These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12791417)

  • 1. Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.
    Agersø H; Vicini P
    Eur J Pharm Sci; 2003 Jun; 19(2-3):141-50. PubMed ID: 12791417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.
    Agersø H; Jensen LB; Elbrønd B; Rolan P; Zdravkovic M
    Diabetologia; 2002 Feb; 45(2):195-202. PubMed ID: 11935150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects.
    Elbrønd B; Jakobsen G; Larsen S; Agersø H; Jensen LB; Rolan P; Sturis J; Hatorp V; Zdravkovic M
    Diabetes Care; 2002 Aug; 25(8):1398-404. PubMed ID: 12145241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.
    Larsen PJ; Fledelius C; Knudsen LB; Tang-Christensen M
    Diabetes; 2001 Nov; 50(11):2530-9. PubMed ID: 11679431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
    Juhl CB; Hollingdal M; Sturis J; Jakobsen G; Agersø H; Veldhuis J; Pørksen N; Schmitz O
    Diabetes; 2002 Feb; 51(2):424-9. PubMed ID: 11812750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.
    Chang AM; Jakobsen G; Sturis J; Smith MJ; Bloem CJ; An B; Galecki A; Halter JB
    Diabetes; 2003 Jul; 52(7):1786-91. PubMed ID: 12829647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs.
    Ribel U; Larsen MO; Rolin B; Carr RD; Wilken M; Sturis J; Westergaard L; Deacon CF; Knudsen LB
    Eur J Pharmacol; 2002 Sep; 451(2):217-25. PubMed ID: 12231394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
    Degn KB; Juhl CB; Sturis J; Jakobsen G; Brock B; Chandramouli V; Rungby J; Landau BR; Schmitz O
    Diabetes; 2004 May; 53(5):1187-94. PubMed ID: 15111485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.
    Rolin B; Larsen MO; Gotfredsen CF; Deacon CF; Carr RD; Wilken M; Knudsen LB
    Am J Physiol Endocrinol Metab; 2002 Oct; 283(4):E745-52. PubMed ID: 12217892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
    Meier JJ; Kemmeries G; Holst JJ; Nauck MA
    Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones.
    Toft-Nielson M; Madsbad S; Holst JJ
    Diabetes; 1996 May; 45(5):552-6. PubMed ID: 8621002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
    Nauck MA; Heimesaat MM; Behle K; Holst JJ; Nauck MS; Ritzel R; Hüfner M; Schmiegel WH
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1239-46. PubMed ID: 11889194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
    Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
    Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabet Med; 2001 Feb; 18(2):144-9. PubMed ID: 11251679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
    Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
    J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide-1: a potent regulator of food intake in humans.
    Gutzwiller JP; Göke B; Drewe J; Hildebrand P; Ketterer S; Handschin D; Winterhalder R; Conen D; Beglinger C
    Gut; 1999 Jan; 44(1):81-6. PubMed ID: 9862830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.
    Pørksen N; Grøfte B; Nyholm B; Holst JJ; Pincus SM; Veldhuis JD; Schmitz O; Butler PC
    Diabetes; 1998 Jan; 47(1):45-9. PubMed ID: 9421373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-I-(7-37) suppresses hyperglycemia in rats.
    Hendrick GK; Gjinovci A; Baxter LA; Mojsov S; Wollheim CB; Habener JF; Weir GC
    Metabolism; 1993 Jan; 42(1):1-6. PubMed ID: 8446036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man.
    Hvidberg A; Nielsen MT; Hilsted J; Orskov C; Holst JJ
    Metabolism; 1994 Jan; 43(1):104-8. PubMed ID: 8289665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect.
    Prigeon RL; Quddusi S; Paty B; D'Alessio DA
    Am J Physiol Endocrinol Metab; 2003 Oct; 285(4):E701-7. PubMed ID: 12773303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.